$6.43
2.58% today
Nasdaq, Apr 01, 06:46 pm CET
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Kura Oncology, Inc. Stock price

$6.60
-1.11 14.40% 1M
-12.94 66.22% 6M
-2.11 24.23% YTD
-15.22 69.75% 1Y
-9.48 58.96% 3Y
-3.35 33.67% 5Y
-8.40 56.00% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.45 6.38%
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Key metrics

Market capitalization $532.98m
Enterprise Value $-177.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -3.30
P/S ratio (TTM) P/S ratio 9.89
P/B ratio (TTM) P/B ratio 1.25
Revenue (TTM) Revenue $53.88m
EBIT (operating result TTM) EBIT $-193.20m
Free Cash Flow (TTM) Free Cash Flow $133.85m
Cash position $727.40m
EPS (TTM) EPS $-2.02
P/E forward negative
P/S forward 3.98
EV/Sales forward negative
Short interest 11.28%
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Kura Oncology, Inc. forecast:

13x Buy
81%
3x Hold
19%

Analyst Opinions

16 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
81%
Hold
19%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
54 54
-
100%
- Direct Costs 0.85 0.85
0% 0%
2%
53 53
6,340% 6,340%
98%
- Selling and Administrative Expenses 75 75
54% 54%
140%
- Research and Development Expense 170 170
47% 47%
315%
-192 -192
17% 17%
-357%
- Depreciation and Amortization 0.85 0.85
0% 0%
2%
EBIT (Operating Income) EBIT -193 -193
17% 17%
-359%
Net Profit -174 -174
14% 14%
-323%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
about 6 hours ago
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a v...
Neutral
GlobeNewsWire
6 days ago
– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing t...
Neutral
GlobeNewsWire
25 days ago
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting...
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today